

## Product datasheet

anti-Keratin K19 mouse monoclonal, Ks19.1 (A53-B/A2), liquid, purified, sample

### Short overview

<b>Cat. No.</b>	690010S
<b>Quantity</b>	200 µl (50 µg/ml)
<b>Concentration</b>	50 µg/ml

### Product description

<b>Host</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Isotype</b>	IgG2a
<b>Formulation</b>	Contains 0.09% sodium azide, 0.5% BSA in PBS buffer, pH 7.4
<b>UniprotID</b>	P08727 (Human)
<b>Synonym</b>	Keratin, type I cytoskeletal 19, Cytokeratin-19, CK-19, Keratin-19, K19, KRT19
<b>Note</b>	Centrifuge prior to opening
<b>Conjugate</b>	Unconjugated
<b>Purification</b>	Affinity chromatography
<b>Storage</b>	Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
<b>Intended use</b>	Research use only
<b>Application</b>	ELISA, ICC/IF, IHC, WB
<b>Reactivity</b>	Human

### Applications

<b>ELISA</b>	Assay dependent
<b>Immunocytochemistry (ICC)</b>	Assay dependent
<b>Immunohistochemistry (IHC) - frozen</b>	1:5-1:50
<b>Immunohistochemistry (IHC) - paraffin</b>	1:5-1:50 (microwave treatment recommended)
<b>Western Blot (WB)</b>	1:50-1:500


### Background

Ks 19.1 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma. Polypeptide reacting: Mr 40,000 polypeptide (keratin K19; formerly also designated cytokeratin 19) of human glandular epithelia. The epitope has been localized on aa. 311-335 (QSQLSMKAALEDTLAETEARFGAQL) of the alpha-helical fragment.


Tumors specifically detected: all tested adenocarcinoma; cholangio carcinoma of liver; renal cell carcinoma; transitional cell carcinoma of the bladder; ovary carcinoma; squamous cell carcinoma of cervix, bronchus and lung (intermediate type); mesothelioma; carcinoid tumor of bronchus; breast carcinoma; thymoma.

Reactivity on cultured cell lines: MCF-7.


## Product images



IHC analysis of human colon using anti-Keratin K19 antibody (Cat. No. 61010). IHC was performed on formalin fixed paraffin embedded sections. The samples were deparaffinized with xylol and ethanol followed by heat induced antigen retrieval with 10 mM citrate buffer. After preparation the tissue was blocked with normal serum for 20 min at RT. The primary antibody anti-Keratin K19 (Cat. No. 61010) was diluted in PBS (antibody concentration 10 µg/ml) and incubated at 4°C over-night. The secondary antibody ImmPRESS HRP anti-mouse IgG was incubated for 20 min at RT. Slides were incubated with DAB solution until a brown staining is visible and with Haemalaun for a few minutes. The picture was acquired using microscopy (courtesy of J. Hess, University Hospital Heidelberg).



Western blot analysis of MCF-7 lysate with anti-Keratin K19 antibody (Cat. No. 61010). Western blot analysis was performed on 5 µg/10 µg MCF-7 lysate. Cells were lysed with RIPA buffer. The PVDF membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-Keratin K19 mouse monoclonal (Cat. No. 61010) was diluted in blocking buffer (antibody concentration 0.5 µg/ml) and incubated for 1 h at RT. The secondary antibody anti-mouse IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 0.2 µg/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.



IHC analysis of human kidney using anti-Keratin K19 antibody. IHC was performed on formalin fixed paraffin embedded sections. The samples were deparaffinized with xylol and ethanol followed by heat induced antigen retrieval with 10 mM citrate buffer. After preparation the tissue was blocked with normal serum for 20 min at RT. The primary antibody anti-Keratin K19 was diluted in PBS (antibody concentration 2 µg/ml) and incubated at 4°C over-night. The secondary antibody ImmPRESS HRP anti-mouse IgG was incubated for 20 min at RT. Slides were incubated with DAB solution until a brown staining is visible and with Haemalaun for a few minutes. The 20x picture was acquired using microscopy (courtesy of J. Hess, University Hospital Heidelberg).

PROGEN Biotechnik GmbH | Maaßstraße 30 | D-69123 Heidelberg

Tel.: +49 (0) 6221 8278-0 | Fax: +49 (0) 6221 8278-24 | Email: [info@progen.com](mailto:info@progen.com) | Web: [www.progen.com](http://www.progen.com)

2025 February 13 / Version: 690010S/DS-280824ibg | Page 2

## References

Publication	Species	Application
<a href="#">Karsten, U. et al. Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur. J. Cancer Clin. Oncol. 21, 733â€“740 (1985).</a>	human	ICC-IF
<a href="#">Sugama, Y. et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn. J. Cancer Res. 85, 1178â€“1184 (1994).</a>	human	ELISA
<a href="#">Grenier, J. et al. Cyfra 21-1, a new marker of lung cancer. Nucl. Med. Biol. 21, 471â€“476 (1994).</a>	human	ELISA
<a href="#">Moll, R. et al. Cytokeratins in normal and malignant transitional epithelium: maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines. Am. J. Pathol. 132, 123â€“144 (1988).</a>	human	IHC (frozen), ICC-IF
<a href="#">Lindberg, K. &amp; Rheinwaldt, J. G. Suprabasal 40 kd Keratin (K19) Expression as an Immunohistologic Marker of Premalignancy in Oral Epithelium. Am. J. Pathol. 134, 89â€“98 (1989).</a>	human	IHC (paraffin)